Background: The simplistically and ambiguously termed 'fibrostenosis' of bowel is a hallmark of severe Crohn's disease [CD] and a major contributor to medical treatment failure. Non-invasive imaging assessment and novel medical therapy targeting this condition are under investigation, which particularly requires a better understanding of the underlying histological basis. Methods: We analysed 48 patients with stricturing Crohn's ileitis or/and colitis that required surgical resection. The most representative sections of the fibrostenotic, non-stenotic and uninvolved regions were reviewed for histological analysis. For each layer of bowel wall (mucosa including muscularis mucosae [MU], submucosa [SM], muscularis propria [MP], subserosal adventitia [SS]), histological abnormalities were evaluated individually, including active and chronic inflammation, fibrosis, smooth muscle hyperplasia or hypertrophy, neuronal hypertrophy and adipocyte proliferation. A novel semiquantitative histological grading scheme was created. Results: The most significant histopathological features characterizing the stricturing intestines were smooth muscle hyperplasia of SM, hypertrophy of MP and chronic inflammation. The muscular alteration was predominant in all layers. The overall muscular hyperplasia/hypertrophy was positively correlated with chronic inflammation and negatively correlated with fibrosis, whereas SM muscular hyperplasia was also associated with MU active inflammation. Similar changes, to a lesser extent, occurred in the adjacent non-stenotic inflamed bowel as well. Conclusions: In CD-associated 'fibrostenosis', it is the smooth muscle hyperplasia/hypertrophy that contributes most to the stricturing phenotype, whereas fibrosis is less significant. The 'inflammation-smooth muscle hyperplasia axis' may be the most important in the pathogenesis of Crohn's strictures.
Introduction
Under the current medical treatment, 10% to 20% of the patients with Crohn's disease [CD] may experience a prolonged remission after initial presentation, but more than half of the patients with Crohn's ileitis or colitis will eventually develop stricturing disease [1, 2] which has been regarded as a characteristic phenotype [B2 phenotype in Montreal classification] and a hallmark of severe CD as well as a major contributor to medical treatment failure and hospitalization with surgical resection. CD-associated stricture is clinically characterized by localized bowel wall stenosis [thickening, hardening and narrowing] causing bowel obstruction, which is a complication of long-lasting and recurring bowel inflammation. [3] This condition is unresponsive to any of the current drugs for CD but requires surgical resection, and it often develops again following postoperative recurrence. Clinically, the fibrostenotic stricture needs to be distinguished from inflammation-related bowel wall thickening which may respond to anti-inflammatory therapy; the two often coexist, and the distinction between the two is difficult at endoscopy or/and cross-sectional imaging. At endoscopy [colonoscopy or balloon-assisted endoscopy], the finding of mucosal ulceration is often assumed to indicate inflammation, and the presence of stricture is thought to represent the highest degree of inflammation and chronicity [4] ; however, routine endoscopy cannot comment on submucosal pathology. Cross-sectional imaging assessment cannot be confidently correlated with the histological complexity or with endoscopic appearance.
Clinically and pathologically, this condition has been commonly termed 'fibrostenosis', which seems to be a simplistic and ambiguous term with a focus on fibrosis. In reality, the detailed underlying histopathological changes in this condition have not been fully and systematically characterized. A better understanding of the histological basis and pathogenesis is particularly important for developing novel targeted therapy and for interpreting non-invasive imaging assessment for this clinically challenging condition.
In the present study, we developed a comprehensive analysis of the histopathological elements in Crohn's 'fibrostenosis' by developing a novel histological grading system that covers not only inflammation and fibrosis but the full spectrum of inflammatory bowel disease pathology. By doing this, we aimed to [i] better understand the full spectrum of histological changes in each layer of bowel wall in this condition and the association between various changes; and [ii] clearly illustrate the histological basis that would help in clinico-pathological assessment and management of CD-associated bowel stricture, e.g. histological correlation with the radiologicalendoscopic assessment, and identification of potential therapeutic targets.
Materials and Methods

Patient selection
A total of 48 patients [male 22, female 26, ages 17 to 67 years] with Crohn's disease complicated by clinical bowel obstruction secondary to well-identified strictures and treated by surgical resection in our institution during the past 5 years were retrieved through search in the Calgary Laboratory Services [CLS] surgical pathology file, and were included in the study. All cases with wellidentified segmental bowel narrowing and thickening, and with at least one clearly stated tissue sample taken from the stricture site, were enrolled. All patients had long-standing Crohn's disease [ileitis or colitis or both] diagnosed clinically and pathologically before the stricture formation, all received various standard medical treatments including biologic therapies and all had surgical resection of the diseased bowel because of bowel obstruction despite anti-inflammatory therapy and/or consideration of endoscopic dilatation. Clinical data were reviewed. The original histopathology reports and glass slides were carefully reviewed for the details. In all cases, marked segmental stenosing stricture was grossly identified.
The study was approved by the University of Calgary Conjoint Health Research Ethics Board.
Macroscopic evaluation
The surgical specimens were sent fresh to the pathology laboratory, and they were examined and processed in a standard routine clinical protocol, including overnight fixation in formalin before sampling. The macroscopic findings were well described in the original pathology reports. In each case, one or more segments of strictured bowel were clearly identified. The data were extracted from the original gross description, including the region and extent of CD involvement, the site of stricture, the length of stricture, the luminal circumference of stricture site, the bowel wall thickness at stricture site and the appearance of the mucosa within stricture [e.g. presence of ulceration, fissuring or fistula etc.].
The macroscopic findings of all cases are summarized in Table 1 . The overall disease location seen in the 48 patients varied: 23 cases had the disease located in terminal ileum only, 6 cases had the disease in colon only and 19 cases had the disease involving ileum and one or more other parts of intestines [13 cases involving both ileum and colon, 1 case involving distal jejunum as well as ileum and colon, 2 cases involving vermiform appendix, 2 cases involving rectum and 1 case involving anal canal]. The stricture site was identified in all the cases [37 in ileum, 11 in colon], with the length of strictures ranging from 2.3 to 30 cm, the luminal circumference of the stricture site ranging from 1.0 to 4.0 cm, and the bowel thickness of the strictured segments ranging from 0.5 to 1.9 cm; 22 cases had mucosal ulceration at the stricture sites and 3 cases had macroscopic fistula within the strictures. For example, in the mucosa layer four categories including active inflammation, chronic inflammation, lamina propria fibrosis and smooth muscle hyperplasia, were included. The active inflammation was composed of five elements, including superficial ulceration, fissuring ulceration, cryptitis, crypt abscess and neutrophil infiltration in lamina propria. Similarly, for chronic inflammation, four elements [lamina propria mononuclear cell cellularity, eosinophil infiltration, lymphoid follicles/aggregates and crypt architecture alteration] were evaluated. The fibrosis was assessed based on the definition commonly used in clinical pathology, i.e. the areas of fibroblast proliferation mixed with collagen and other matrix deposition forming scar-like fibrous tissue, and it was scored by its extent within each layer, mainly in mucosa and submucosa. The smooth muscle hyperplasia [proliferation] was defined as 'visible marked smooth muscle bundles dissection [in mucosa or submucosa]', and the smooth muscle hypertrophy [of muscularis propria] was defined as 'marked thickening of smooth muscle layers as compared with normal or relatively normal bowel in the adjacent region'. Furthermore, the weight of each category was determined by scoring/grading each histopathological element [0 = absent, 1 = mild, 2 = moderate, and 3 = severe] and summing the total score under each category. [See more details in Table 2 ]. Based on these, a novel comprehensive semiquantitative grading/scoring scheme was designed by one of the authors [XG] . The space volume [thickness] expansion of each layer was also graded by comparing the thickness of the layer with that of the relatively normal regions of the same intestinal tract [resection margins], and a score was given based on the ratio of the two.
Microscopic assessment
For each layer, four 100× microscopic fields were scored and the average score was obtained on each histopathological component. The total score for each category [active inflammation, chronic inflammation, fibrosis, muscular hyperplasia/hypertrophy, neuronal hyperplasia, adipocyte hyperplasia, volume expansion] in each layer was obtained by calculating the sum of the scores of all components under that category. Considering that the composition and the possible maximum total score of a particular category for different layers were not exactly the same, the score was further adjusted for comparison by calculating its percentage [%] of the possible maximum total score [PMTS] for each category for each layer: adjusted score [%] = [actual total score/PMTS] × 100. For example, for scoring active inflammation in mucosa there were five components included, and the possible maximum total score would be [5 × 3 = 15] .
For each case, a global score of each category for the whole bowel wall was also obtained by getting the sum of the scores of the particular category in each layer [e.g., the global score of active inflammation is obtained by adding up the total scores of active inflammation in mucosa, submucosa, muscularis propria and subserosal adventitia]. The adjusted scores [% PMTS] of the global scores were calculated in the same way, as described above.
Additionally, a comparison between the stenotic strictured bowel, adjacent inflamed but non-stenotic bowel and relatively normal region was made in each case with regard to all histological parameters.
For each case, the histological assessment and scoring were conducted by two independent pathologists [WC and XG], and the average scores were obtained for further analyses. Rare difficult cases or discrepancies were re-evaluated to achieve consensus.
In our final analysis for presenting the results in this paper, the data regarding the subserosal adventitia were not included since in some cases this part of bowel wall was not fully sampled.
We also performed Masson's Trichrome stain and immunohistochemical stain for smooth muscle actin [SMA] [antibody used: antiActin α, smooth muscle, mouse monoclonal, clone 1A4; Sigma, St. Louis, MO, USA. Dilution used: 1/32 000] to highlight the fibrosis and smooth muscle components, respectively, following the gradings on H&E slides. We confirmed an identical grading of fibrosis and smooth muscle components between the special/immunohistochemical stains and H&E stain.
Additionally in randomly selected cases, immunostain for desmin [antibody used: anti-human desmin, mouse monoclonal, clone D30; Dako, Glostrup, Denmark. Dilution used: 1/100] was also performed to distinguish between smooth muscle cells [known to express both SMA and desmin] and myofibroblasts [known to express SMA only], although the morphological distinction between the two is usually not difficult to the eyes of a histopathologist.
Furthermore, a possible correlation between some of the histopathological categories, e.g., chronic inflammation and fibrosis, was analysed.
Lastly, the ileal strictures and colonic strictures were compared by layer and by their global scores. Table 3 shows the average of the total scores as well as the adjusted scores [% PMTS] for each histopathological category [active inflammation, chronic inflammation, fibrosis, muscular hyperplasia/hypertrophy, adipocyte hyperplasia, and neuronal hypertrophy] in each layer of bowel wall. The results of the three different regions of bowel are also compared. Figure 1A shows the diagram 
Statistical analysis
Results
Muscularis propria hypertrophy is the most predominant change
As seen in Figure 1 , 2 and Table 3 , of all bowel wall layers in the strictures, the volume expansion [thickening] was most significantly seen in the muscularis propria of which the average thickness was over two folds of adjacent uninvolved bowel, as shown in Figure 2B , C. Figure 2D , E. The fibrosis and adipocyte hyperplasia in the same layer were minimal. The space volume of submucosa was moderately expanded, slightly over 1-fold of normal on average, whereas the mucosal thickness only mildly increased.
Smooth muscle migration and hyperplasia are prominent in the submucosa
The space volume of submucosa was moderately expanded, slightly over 1-fold of normal on average. As shown in Figure 3 , within the thickened submucosa layer, a significant amount of haphazardly arranged smooth muscle bundles were present, intermingled with fibrosis [ Figure 3A -C]. Part of the smooth muscle bundles appeared to originate from both outward dissection of loosened muscularis mucosae and inward extension of the upper portion of the muscularis propria. In addition, considerable smooth muscle cells appeared to be arising from and proliferating within the stroma [ Figure 3D -F. Overall, the average adjusted score of the smooth muscle hyperplasia was 70.8% [equivalent to approximately 1/3 to 2/3 occupancy of the entire submucosal space]. Neuronal hypertrophy was also an accompanying feature.
Submucosal fibrosis, in contrast, only reached an average adjusted score of 43.6% [equivalent to little more than 1/3 of occupancy of submucosal space]. Similarly, adipocyte proliferation also occupied less than 1/3 of submucosal space.
Notably, the majority of the SMA-positive proliferating cells were also desmin positive, whereas the adjacent pericryptal myofibroblasts were SMA positive but desmin negative [ Figure 4 ]. This finding indicates that there is indeed mature and immature smooth muscle cell proliferation rather than just the expansion of stromal myofibroblasts.
Smooth muscle dissection and proliferation in mucosa
The mucosa layer was also mildly thickened, partly due to lamina propria expansion by oedema and lymphoplasmacytic infiltration, although its thickness was difficult to assess accurately due to the presence of mucosal ulceration in many cases. Smooth muscle hyperplasia was also present in the mucosa layer, and it was characterized by thickening and loosening of the muscularis mucosae with inward dissection into lamina propria [ Figure 5A -C] as well as outward dissection into submucosa [ Figure 5D ]. In addition, seemingly in situ proliferation of smooth muscle cells in lamina propria was also noticed [ Figure 5E -E shows an example] in some cases. The average adjusted score of this component reached 77.8%, largely due to a 2-to 3-fold thickening of muscularis mucosa accompanied by inward vertical dissection.
Chronic inflammation throughout all layers is the second most significant change following neuromuscular hyperplasia/hypertrophy
As shown in Table 3 and Figure 1 , the average adjusted score of chronic inflammation was the second highest observation in all layers, especially in the mucosa and submucosa. When assessed by the In all three layers, the smooth muscle hyperplasia/hypertrophy was the most predominant change, followed by chronic inflammation.
[B] When combining the three layers as a whole, the global score of each histological change was obtained. The combined muscular hyperplasia and hypertrophy was still the most predominant feature, followed by neuronal hypertrophy and chronic inflammation. PMTS, possible maximum total score. global scores [ Figure 1B ], chronic inflammation came as the third highest observation following muscular and neuronal hyperplasia/ hypertrophy, whereas the weight of active inflammation was much lower in general. On the other hand, there were no cases of 'fibrostenotic' bowel that were completely non-inflamed.
Fibrosis is in fact the least significant change
As compared with the adjusted score, fibrosis was the least significant change, except in the submucosa in which fibrosis ranked third of the top changes, as shown in Table 3 and Figure 1 .
Involvement of subserosal adventitia
The findings in subserosal adventitia were not taken into further analysis due to incomplete or detached tissue sampling in some of the cases. In those with intact samples [approximately 70% of all cases], it appeared that the subserosal adventitia was also involved by similar histopathological changes, largely chronic inflammation and fibrosis. Smooth muscle hyperplasia was present as well but less prominent, including muscle bundles extending from longitudinal muscle layer and local smooth muscle cell proliferation [ Figure 5F shows an example]. 
Association between different histopathological changes
As shown in Table 4 and Figure 6 , when looking into the different compartments of the bowel wall, the smooth muscle hyperplasia in In other words, when the muscular hyperplasia/hypertrophy became prevalent, the fibrosis was relatively less.
Similar changes in the non-stenotic inflamed bowel
As seen in Table 3 , the adjacent inflamed but non-stenotic bowel also showed a significant, but to a much less extent, muscular hyperplasia/ hypertrophy in submucosa and muscularis propria accompanied by neuronal hypertrophy. Similarly, fibrosis occurred as well but was less significant as compared with muscular changes. The degree of both active and chronic inflammation, especially in the deeper layers, was in general less than that in the strictured bowel [p-values ranged from 0.0001 to 0.001 for all of the analyses]. MUAI, mucosa active inflammation; MUFS, mucosa fibrosis; SMFS, submucosa fibrosis; SMMH, submucosa muscular hyperplasia; SMNH, submucosa neuronal hypertrophy; MPMH, muscularis propria muscular hypertrophy; MPNH, muscularis propria neuronal hypertrophy; AI, active inflammation (global); CI, chronic inflammation (global); FS, fibrosis (global); MPH, muscular proliferation and hypertrophy (global); Y, yes.
Comparison between ileal and colonic strictures
As shown in Table 5 , a few differences existed between the cases of ileitis-associated [ileal] and colitis-associated [colonic] strictures [n = 37 and 11, respectively]. Notably, the degree of muscular hyperplasia/hypertrophy in each layer was significantly higher in the ileal lesions than in the colonic lesions [p = 0.001, 0.012 and 0.045, respectively], whereas fibrosis in the submucosa and muscularis propria was significantly higher in colonic lesions compared with ileal lesions [p = 0.017 and 0.045, respectively].
Discussion
The development of the so-called 'fibrostenosis' in Crohn's disease has been considered to be the result of an unbalanced and exaggerated tissue remodelling secondary to local deep and repetitive inflammation and tissue damage. As the terminology itself implies, this condition has been commonly believed to be essentially fibrotic [i.e. fibroblast proliferation with collagen deposition in stroma] in nature. Almost all of the studies so far have focused on fibrosis/fibrogenesis. In clinical terms, often a distinction is made between fibrostenotic disease and inflammatory stenosis of the bowel lumen and therapy is guided accordingly. Our study shows that the real picture is histologically more complex.
Theoretically, several histological changes could contribute to the bowel wall thickening and stricturing, including fibrosis, hyperplasia of fat [adipose] and/or smooth muscle tissues, and even oedema as a part of inflammation. Systematic histopathological characterization of Crohn's fibrostenotic stricture has been very limited. Most of the published histopathological evaluations of this condition were performed as a part of radiological studies [ultrasound or CT], with various histological grading schemes roughly assessing for inflammation and fibrosis. [5] [6] [7] [8] Recently, Schaeffer et al. proposed a scoring system for semi-quantitative histological analysis of CD in surgical resection specimens to evaluate the changes related to anti-tumour necrosis factor [TNF] therapy [9] . However, a universal or widely accepted histological grading system for this condition is not yet available. To meet the needs of our study, we have developed a novel system that incorporates and modifies several of the previously published schemes, and we have proven its usefulness.
The most interesting and important finding in our study is that the muscularization, including hypertrophy of the muscular propria and smooth muscle hyperplasia of the submucosa, is the most prevalent histological change in the condition of fibrostensis, whereas the fibrosis is in fact much less significant in magnitude of its presence and as such contribution to stenosis. The primary volume-expanding compartment is also the muscular layer. Moreover, such changes start before the fibrostenotic phenotype appears. In clinical practice of Crohn's disease management, this is rarely appreciated.
The phenomenon of smooth muscle hyperplasia/hypertrophy in CD has been noted briefly in literature, but lacks extensive clinical recognition. In the 1980s, by using transmission electron microscopy, Dvorak et al. reported that the smooth muscle cells of muscularis propria were altered, with hypertrophy and collagen deposition. [10] In 2001, Koukoulis et al. showed obliterative muscularization of the submucosa in surgical specimens of CD-related bowel strictures. [11] A few years ago, Suekane et al. demonstrated an accumulation of smooth muscle cells in submucosa in CD-related strictures by using immunohistochemistry to study the differentiation of mesenchymal cells. They also found that those transforming smooth muscle cells were immunohistochemically positive for angiotensin II type 1 receptor, and therefore proposed a possible role of the angiotensin II system in the development of Crohn's fibrostenosis [.12] We also demonstrated that the degree of muscular hyperplasia/ hypertrophy is positively associated with the severity of chronic inflammation of the bowel wall, and negatively associated with the degree of fibrosis. This may suggest a dissociation of the two processes, with involvement of independent pathways. It also indicates that efforts to inhibit of fibrosis may not be sufficient to inhibit or reverse intestinal narrowing.
Our findings suggest that the 'inflammation-smooth muscle proliferation' axis seems to be more, or at least equally, important as compared with fibrogenic processes in the development of Crohn's stricture and in the consideration of future therapeutic targets. Further studies on the underlying biochemical and molecular mechanisms will be necessary. Certainly, our observations also need to be further validated by inter-observer agreement.
Tissue remodelling processes secondary to an excessive wound healing response are characterized by proliferation of mesenchymal cells [including fibroblasts, myofibroblasts and smooth muscle cells], differentiation of myofibroblasts, hypertrophy of smooth muscle cells and accumulation of excess extracellular matrix proteins. [13] When these changes occur in the bowel, bowel wall thickening as a consequence would be expected, and bowel stricture and resulting obstruction may follow.
In wound healing processes it is generally the cytokines and chemokines released by immune cells that drive the inflammatory response. [14] In a setting of mucosal tissue damage as seen in CD, under the stimulation of certain cytokines such as transforming growth factor-β [TGF-β], insulin-like growth factor [IGF], plateletderived growth factor-AB [PDGF-AB] and epidermal growth factor [EGF], the subepithelial myofibroblast would migrate to the wound area and produce extracellular matrix that is critical for wound healing. [15, 16] The myofibroblasts could arise from various sources: proliferation of existing tissue fibroblasts, recruitment of fibroblasts, recruitment of precursor mesenchymal stem cells from the bone marrow, transformation of either epithelial cells [via epithelial-tomesenchymal transition] or endothelial cells [via endothelial-to-mesenchymal transition]. The relative contribution of these processes in chronic inflammation is unclear.
Earlier investigations reported that excessive collagen deposition in CD-affected bowel resulted from the proliferation of fibroblasts in response to inflammatory mediators such as TGF-β, TNF-α and IL-1β. [17] [18] [19] [20] Recent studies also proposed that epithelial-mesenchymal transition may serve an important role in the development of CD-associated fibrostenosis. [21] In hollow organs such as intestines, airways and blood vessels, alterations of the smooth muscle secondary to the overlying mucosal inflammation or injury are commonly seen and have been extensively studied. A two-way communication between mucosal epithelial cells and smooth muscle cells, as well as between immune cells and smooth muscle cells, appears to exist, although the pathways involved in the process remain to be fully elucidated. [22] Numerous [23, 24] For example, TGF-β1 and IGF were found to promote the growth of smooth muscle cells. [25, 26] In addition, myofibroblast differentiation in the mesenchyma is a common and key player in chronic inflammation and wound healing processes, involving stimulations by various cytokines. [27] [28] [29] Myofibroblasts are also a common resident cell population in the intestines, including subepithelial myofibroblasts, pericryptal myofibroblasts and interstitial cells of Cajal. Activated myofibroblasts also exhibit migratory potential, [29] and may transform into smooth muscle cells under certain conditions. [30] [31] [32] On the other hand, a complex interaction between the extracellular matrix and smooth muscle cells is also involved in many disease states and tissue repairing processes. [33] Based on all of our observations, we propose that in a condition like CD-associated stenosis there are possible sequential changes following a 'chronic inflammation-fibrosis-smooth muscle hyperplasia' axis. With the chronic stimulation of pro-inflammatory cytokines released during chronic inflammation, the fibrosis is predominant initially and there would be prominent proliferation of myofibroblasts, largely in the submucosa compartment. When the fibrogenic process continues and becomes uncontrolled with the existence of constant and/or repetitive inflammatory stimuli, the myofibroblasts can differentiate into smooth muscle cells and result in a 'muscularized stricture' phase, which is characterized by the significant smooth muscle hyperplasia/hypertrophy.
A similar concept has been well established in chronic asthma, in which the airway remodelling develops in the form of airway wall thickening caused by smooth muscle hyperplasia secondary to the stimulation of cytokines released during chronic inflammation. [34] [35] [36] In addition to inhaled steroids, immunotherapy targeting certain cytokines or chemokines has been quite successful in asthma treatment. [37, 38] Since the 'stricturing' phenotype of CD shares similar triggers [chronic inflammation] and similar histological features [smooth muscle hyperplasia], it is reasonable to postulate that these two similar conditions in different organs may also share similar pathophysiological mechanisms, particularly in terms of the development of smooth muscle hyperplasia. This may shed some light in pursuing medical treatment to prevent and inhibit the development of the 'stricturing' phenotype in Crohn's disease, and perhaps even reverse it.
It is also interesting to notice that the ileal lesions seem to have a higher degree of muscular changes but less fibrosis as compared with the colonic lesions. We have no solid explanation for the difference, although we postulate that it may be due to many differences between ileal and colonic Crohn's diseases in the mucosal immune reaction [T cell subtypes and cytokines] patterns, genetics and microbiota . [39] [40] [41] [42] 
